(8S,9R,10S,11S,13S,14S,16S,17R)-9-Chloro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-17-carboxylic acid | 37927-35-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (8S,9R,10S,11S,13S,14S,16S,17R)-9-Chloro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-17-carboxylic acid
• 英文别名: (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carboxylic acid
• CAS: 37927-35-8
• 化学式: C₂₁H₂₇ClO₅
• 分子量: 394.895
• InChiKey: LIONZWJHOCJXMT-IFUSVGBSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  27
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  94.8
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (8S,9R,10S,11S,13S,14S,16S,17R)-9-Chloro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-17-carboxylic acid 以 乙醚 、 丙酮 为溶剂， 生成
  参考文献：
  名称：

  Androstane-17beta-carboxylic acids and processes for the preparation thereof

  摘要：

  公开号：

  US03828080A1
• 作为产物：
  描述：

  倍氯米松 在 高碘酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 2.0h， 生成 (8S,9R,10S,11S,13S,14S,16S,17R)-9-Chloro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-17-carboxylic acid
  参考文献：
  名称：

  大环内酯类：一类新型的抗炎化合物

  摘要：

  通过将有效的糖皮质激素类固醇与大环内酯类化合物结合在一起，引入了安全糖皮质激素治疗设计的新概念。这些化合物是由9-deokso-9a-aza-9a-同反霉素A和3-descladinosyl-9-deokso-9a-aza-9a-的各种类固醇17β-羧酸和9a- N-（3-氨基烷基）衍生物合成的使用稳定的烷基链的同型阿霉素。结合大环内酯类化合物优先在免疫细胞（特别是吞噬细胞）中积累的特性与经典类固醇的抗炎活性，我们设计了在卵白蛋白（OVA）诱导的哮喘大鼠中表现出良好抗炎活性的分子。描述了这种新型化合物的合成，体外和体内抗炎活性。

  DOI：

  10.1016/j.bmc.2012.10.036

文献信息

• ANDROSTENE DERIVATIVES
  申请人：Soft Drugs, Inc.

  公开号：EP0902789B1

  公开（公告）日：2002-01-23
• Efficient Interfacially Driven Vehiculization of Corticosteroids by Pulmonary Surfactant
  作者：Alberto Hidalgo、Fabrizio Salomone、Nieves Fresno、Guillermo Orellana、Antonio Cruz、Jesus Perez-Gil

  DOI：10.1021/acs.langmuir.7b01177

  日期：2017.8.15

  Pulmonary surfactant is a crucial system to stabilize the respiratory air liquid interface. Furthermore, pulmonary surfactant has been proposed as an effective method for targeting drugs to the lungs. However, few studies have examined in detail the mechanisms of incorporation of drugs into surfactant, the impact of the presence of drugs on pulmonary surfactant performance at the interface under physiologically meaningful conditions, or the ability of pulmonary surfactant to use the air liquid interface to vehiculise drugs to long distances. This study focuses on the ability of pulmonary surfactant to interfacially vehiculize corticosteroids such as beclomethasone dipropionate (BDP) or Budesonide (BUD) as model drugs. The main objectives have been to (a) characterize the incorporation of corticosteroids into natural and synthetic surfactants,. (b) evaluate whether the presence of corticosteroids affects surfactant functionality, and (c) determine whether surfactant preparations enable the efficient spreading and distribution of BDP and BUD along the air liquid interface. We have compared the performance of a purified surfactant from porcine lungs and two clinical surfactants: Poractant alfa, a natural surfactant of animal origin extensively used to treat premature babies, and CHF5633, a new synthetic surfactant preparation currently under clinical trials. Both, natural and clinical surfactants spontaneously incorporated corticosteroids up to at least 10% by mass with respect to phospholipid content. The presence of the drugs did not interfere with their ability.to efficiently adsorb into air liquid interfaces and form surface active films able to reach and sustain very low surface tensions (<2 mN/m) under compression expansion cycling mimicking breathing dynamics. Furthermore, the combination of clinical surfactant with corticosteroids efficiently promoted the active diffusion of the drug to long distances along the air liquid interface. This effect could not be mimicked by vehiculisation of corticosteroids in liposomes or in micellar emulsions similar to the formulations currently in use to deliver anti-inflammatory corticosteroids through inhalation.
• US4263289A
  申请人：——

  公开号：US4263289A

  公开（公告）日：1981-04-21
• US4310466A
  申请人：——

  公开号：US4310466A

  公开（公告）日：1982-01-12